



(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention
of the grant of the patent:
15.01.2003 Bulletin 2003/03

(21) Application number: **00913448.7**

(22) Date of filing: **14.02.2000**

(51) Int Cl.7: **A61K 9/51**

(86) International application number:
PCT/US00/03676

(87) International publication number:
WO 00/051572 (08.09.2000 Gazette 2000/36)

(54) **USE OF PEG-DERIVATIZED LIPIDS AS SURFACE STABILIZERS FOR NANOPARTICULATE COMPOSITIONS**

VERWENDUNG VON PEG-DERIVATISIERTEN LIPIDEN ALS OBERFLÄCHENSTABILISATOREN FÜR NANOPARTIKULIERTE ZUSAMMENSETZUNGEN

LIPIDES DERIVES DU P.E.G. UTILISES EN TANT QUE STABILISATEURS DE SURFACE POUR DES COMPOSITIONS DE NANOPARTICULES

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**

(30) Priority: **03.03.1999 US 261151**

(43) Date of publication of application:
28.11.2001 Bulletin 2001/48

(73) Proprietor: **Elan Pharma International Limited
Shannon, Clare County (IE)**

(72) Inventors:
• **LIVERSIDGE, Elaine
West Chester, PA 19380 (US)**
• **GOTTARDY, Greta, A.
Lansdale, PA 19446 (US)**

(74) Representative: **Pohlman, Sandra M.
Dörries Frank-Molnia & Pohlman,
Triftstrasse 13
80538 München (DE)**

(56) References cited:
EP-A- 0 499 299 WO-A-90/07923

- **ISMAILOS, GEORGE; ET AL.: "Enhancement of cyclosporin A solubility by d-alpha-tocopheryl-polyethylene-glycol-100 0 succinate (TPGS)." EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 1, no. 5, 1994, pages 269-271, XP000196248**

Description

FIELD OF THE INVENTION

5 [0001] The present invention is directed to nanoparticulate formulations of a drug having at least one polyethylene glycol (PEG)-derivatized phospholipid, PEG-derivatized cholesterol, PEG-derivatized cholesterol derivative, PEG-derivatized vitamin A, or PEG-derivatized vitamin E adsorbed on the surface of the drug as a surface stabilizer, and methods of making and using such compositions.

10 BACKGROUND OF THE INVENTION

[0002] Nanoparticulate compositions, first described in U.S. Patent No. 5,145,684 ("the '684 patent"), are particles consisting of a poorly soluble therapeutic or diagnostic agent having adsorbed onto the surface thereof a non-crosslinked surface stabilizer. The '684 patent describes the use of a variety of surface stabilizers for nanoparticulate compositions. The use of a PEG-derivatized phospholipid, PEG-derivatized cholesterol, PEG-derivatized cholesterol derivative, PEG-derivatized vitamin A, or PEG-derivatized vitamin E as a surface stabilizer for nanoparticulate compositions, or any other component of such compositions, is not described by the '684 patent.

15 [0003] The '684 patent describes a method of screening drugs to identify useful surface stabilizers that enable the production of a nanoparticulate composition. Not all surface stabilizers will function to produce a stable, non-agglomerated nanoparticulate composition for all drugs. Moreover, known surface stabilizers may be unable to produce a stable, non-agglomerated nanoparticulate composition for certain drugs. Thus, there is a need in the art to identify new surface stabilizers useful in making nanoparticulate compositions. Additionally, such new surface stabilizers may have superior properties over prior known surface stabilizers.

25 A. Lipids In Nanoparticulate Compositions

[0004] A lipid is an inclusive term for fats and fat-derived materials. It includes all substances which are (i) relatively insoluble in water but soluble in organic solvents (benzene, chloroform, acetone, ether, *etc.*); (ii) related either actually or potentially to fatty acid esters, fatty alcohols, sterols, waxes, *etc.*; and (iii) utilizable by the animal organism. Because lipids are relatively insoluble in water, but soluble in organic solvents, lipids are often referred to as "fat soluble," denoting substances extracted from animal or vegetable cells by nonpolar or "fat" solvents. Exemplary lipids include phospholipids (such as phosphatidylcholine, phosphatidylethanolamine, and cephalin), fats, fatty acids, glycerides and glycerol ethers, sphingolipids, alcohols and waxes, terpenes, steroids, and "fat soluble" vitamins A or E, which are non-cholesterol based poorly water soluble vitamins. *Stedman's Medical Dictionary*, 25th Edition, pp. 884 (Williams & Wilkins, Baltimore, MD, 1990); *Hawley's Condensed Chemical Dictionary*, 11th Edition, pp. 704 (Van Nostrand Reinhold Co., New York, 1987).

35 [0005] A number of U.S. patents teach the use of a charged phospholipid, such as dimyristoyl phosphatidyl glycerol, as an auxiliary surface stabilizer for nanoparticulate compositions. See *e.g.*, U.S. Patent No. 5,834,025 for "Reduction of Intravenously Administered Nanoparticulate-Formulation-Induced Adverse Physiological Reactions"; U.S. Patent No. 5,747,001 for "Aerosols Containing Beclomethasone Nanoparticle Dispersions"; and U.S. Patent No. 5,718,919 for "Nanoparticles Containing the R(-)Enantiomer of Ibuprofen."

40 [0006] Other U.S. patents describe the use of a charged phospholipid, such as diacylphosphatidyl glycerol or dimyristoyl phosphatidyl glycerol, as a cloud point modifier for the surface stabilizer of a nanoparticulate composition to prevent particle aggregation during steam heat autoclaving. See *e.g.*, U.S. Patent No. 5,670,136 for "2,4,6-triiodo-5-substituted-amino-isophthalate Esters Useful as X-ray Contrast Agents for Medical Diagnostics Imaging"; U.S. Patent No. 5,668,196 for "3-amido-triiodophenyl Esters as X-ray Contrast Agents"; U.S. Patent No. 5,643,552 for "Nanoparticulate Diagnostic Mixed Carbonic Anhydrides as X-ray Contrast Agents for Blood Pool and Lymphatic System Imaging"; U.S. Patent No. 5,470,583 for "Method of Preparing Nanoparticle Compositions Containing Charged Phospholipids to Reduce Aggregation"; and U.S. Patent No. 5,336,507 for "Use of Charged Phospholipids to Reduce Nanoparticle Aggregation." None of these patents refer to the use of a PEG-derivatized phospholipid, PEG-derivatized cholesterol, PEG-derivatized cholesterol derivative, PEG-derivatized vitamin A, or PEG-derivatized vitamin E in nanoparticulate compositions, either as a surface stabilizer, cloud point modifier, or as any other constituent of a nanoparticulate composition.

55 B. PEG-derivatized Lipids in Pharmaceutical Compositions


[0007] Liposomes, or vesicles composed of single or multiple phospholipid bilayers, have been investigated as possible carriers for drugs. Unmodified liposomes tend to be taken up in the liver and spleen. For drugs targeted to these

areas, unmodified liposomes are useful drug adjuvants. However, often the liver and spleen **are not** the target areas for drug delivery. This affinity for the liver and spleen limits the effectiveness of liposome-encapsulated drugs and complicates dosing. Kimelberg et al., "Properties and Biological Effects of Liposomes and Their Uses in Pharmacology and Toxicology," *CRC Crit. Rev. Toxicol.*, 6:25-79 (1978); and Allen et al., "Stealth® Liposomes: An Improved Sustained Release System For 1-beta-D-arabinofuranosylcytosine," *Cancer Res.*, 52:2431-2439 (1992). To avoid these problems, researchers have studied various ways of modifying the liposome structure to prolong circulation time. Allen, *Cancer Res.*, 52:2431-2439 (1992).

[0008] It was discovered that one useful type of modified lipid contains polyethylene glycol (PEG). In its most common form PEG, also known as poly(ethylene oxide) (PEO), is a linear polymer terminated at each end with hydroxyl groups:



This polymer can be represented as HO-PEG-OH, where it is understood that the -PEG-symbol represents the following structural unit:




[0009] PEG is particularly useful because of its ease of preparation, relatively low cost, controllability of the molecular weight, and the ability to link to lipid by various methods. PEG is believed to act by forming a hydrophilic coat and by causing steric hindrance at the liposome surface, thus reducing liposome-serum protein interaction and liposome-RES (reticuloendothelial system) cells interaction. Yuda et al., "Prolongation of Liposome Circulation Time by Various Derivatives of Polyethyleneglycols," *Biol. Pharm. Bull.*, 19:1347-1351, 1347-1348 (1996).

[0010] PEG-derivatized lipids are described in, for example, U.S. Patent No. 5,672,662 ("the '662 Patent") for "Poly (Ethylene Glycol) and Related Polymers Monosubstituted with Propionic or Butanoic Acids and Functional Derivatives Thereof for Biotechnical Applications," and Yuda et al. (1996).

1. PEG-Derivatized Lipid Drug Carriers Result in Increased *In Vivo* Circulation Times of the Administered Drug

[0011] PEG derivatized lipids or liposomes are referred to as "sterically stabilized" lipids or liposomes (S-lipids or S-liposomes). Allen, "Long-circulating (sterically stabilized) liposomes for targeted drug delivery," *TIPS*, 15:215-220 (1994). PEG attracts water to the lipid surface, thus forming a hydrophilic surface on the lipid. The hydrophilic surface inhibits opsonization of the lipid by plasma proteins, leading to increased survival times of PEG-lipid in the circulation. Opsonization refers to uptake by the cells of the mononuclear phagocyte system (MPS), located primarily in the liver and spleen. Because PEG-derivatized lipids evade the cells of the MPS, they are often called Stealth® lipid or liposomes. Lasic D., "Liposomes," *Am. Scientist*, 80:20-31 (1992); Papahadjopoulos et al., "Sterically Stabilized Liposomes; Pronounced Improvements in Blood Clearance, Tissue Distribution, and Therapeutic Index of Encapsulated Drugs Against Implanted Tumors," *PNAS, USA*, 88:11460-11464 (1991). (Stealth® is a registered trade mark of Liposome Technology, Inc., Menlo Park, CA.)

[0012] The diagram below shows a representative PEG-liposome as compared to a conventional liposome:



[0013] PEG-lipids are highly superior over conventional lipids as they exhibit: (1) prolonged blood residence times, (2) a decreased rate and extent of uptake into the MPS with reduced chance of adverse effects to this important host defense system, (3) dose-independent pharmacokinetics in animals and humans, and (4) the ability to cross *in vivo* biological barriers. Allen et al. at 216; Yuda et al. at 1349-1351; Bedu-Addo et al., "Interaction of PEG-phospholipid Conjugates with Phospholipid Implications in Liposomal Drug Delivery," *Advanced Drug Delivery Reviews*, 16:235-247 (1995); and Lasic et al., "The 'Stealth' Liposome: A Prototypical Biomaterial," *Chemical Reviews*, 95:2601-2628 (1995).

[0014] For example, it has been reported that PEG-derivatized lipids can result in a great increase in the blood circulation lifetime of the particles. Studies of doxorubicin and epirubicin encapsulated in PEG-phospholipids for decreasing tumor size and growth showed that the encapsulated drugs had a much longer half-life than free drug and are cleared much more slowly from the circulation (for PEG-phospholipid encapsulated doxorubicin, the distribution half-life was about 42 hours, in contrast to the distribution half-life of about 5 minutes for free doxorubicin). The '662 Patent; Mayhew et al., *Int. J. Cancer*, 51:302-309 (1992); Huang et al., *Cancer Res.*, 52:6774-6781 (1992); and Gabizon et al., "A Pilot Study of Doxorubicin Encapsulated in Long-Circulating (Stealth®) Liposomes (S-Dox) In Cancer Patients," *Proc. Am. Soc. Clin. Oncol.* 11:124 (1992).

[0015] Similarly, Yuda et al. describe prolongation of the *in vivo* circulation time of PEG-derivatized lipids, such as PEG-derivatized cholesterol, PEG-derivatized succinate, PEG-derivatized phosphatides, and PEG-derivatized glycerols. The results showed that incorporation of the PEG-derivatives into liposomes appreciably increased the blood level of liposomes and correspondingly decreased the RES uptake after injection. Conventional liposomes without PEG showed low blood levels and high accumulation in the liver and spleen, suggesting that these liposomes were readily taken up by the RES. Yuda et al. at 1349.

2. PEG-Derivatized Lipid Drug Carriers Result in Decreased Toxicity of the Administered Drug

[0016] In addition to the prolonged half-life of drugs when encapsulated in PEG-derivatized lipids, it was also determined that toxicity of the administered drug is reduced compared to that observed with administration of free drug in animals. This reduction in toxicity is likely because the PEG-liposome carrier prevents a large post-administration spike in plasma levels. Mayhew et al., *Int. J. Cancer*, 51:302-309 (1992).

3. PEG-Derivatized Lipid Drug Carriers Result in Increased Stability of the Administered Drug

[0017] Another way in which long-circulating PEG-lipids may enhance cytotoxic cell delivery is by protecting drugs that rapidly degrade from contact with plasma for prolonged periods. For example, in a study of mice bearing leukemia tumors, ARA-C (an unstable drug) encapsulated in PEG-derivatized phospholipids was more effective at lower doses in prolonging survival time of mice than was free ARA-C or ARA-C entrapped in conventional liposomes. Allen et al., *Cancer Res.*, 52:2431-2439 (1992). The superiority of the PEG-derivatized phospholipid delivery system to other drug delivery systems at low doses was attributed to the greatly extended circulation time of the PEG-derivatized lipids, as

well as to slow leakage rates of the drug from the carrier.

[0018] Additional PEG-lipid publications include WO 90/07923, which describes that compositions for the administration of protein or peptide drugs across membranes show low toxicity and efficient permeation when the medium is a mixture of bile salt or fusidate with a nonionic detergent.

5 [0019] Hosoda et al., *Biol. Pharm. Bull.*, 18:1234-1237 (1995), refers to encapsulation of doxorubicin in PEG-coated liposomes.

[0020] Similarly, Horowitz et al., "Folate-targeted liposomes with Entrapped Doxorubicin ...," in Pfeleiderer et al., *Chemistry and Biology of Pteridines and Folates*, 11th Symposium, 1997, refers to folate-targeted liposomes with entrapped doxorubicin.

10 [0021] Papahadjopoulos et al., *PNAS. USA.*, 88:11460-11464 (1991), is directed to liposome carrier systems for macromolecules.

[0022] Finally, Lee et al., *J. Biol. Chem.*, 271:8481-8487 (1996), refers to a lipid gene transfer vector entrapped in anionic liposomes.

15 [0023] There is a need in the art for nanoparticulate compositions of poorly soluble drugs having potentially long blood pool residence times, decreased toxicity, and increased stability to increase the effectiveness of the administered drug, and for methods of making such compositions. In addition, there is a need in the art for a surface stabilizer useful in preparing nanoparticulate compositions of drugs, in which prior known surface stabilizers are ineffective. The present invention satisfies these needs.

20 SUMMARY OF THE INVENTION

[0024] The present invention is directed to nanoparticulate compositions comprising a poorly soluble drug and at least one PEG-derivatized phospholipid ("PEG-phospholipid"), PEG-derivatized cholesterol ("PEG-cholesterol"), PEG-derivatized cholesterol derivative ("PEG-cholesterol derivative"), PEG-derivatized vitamin A ("PEG-vitamin A"), or

25 PEG-derivatized vitamin E ("PEG-vitamin E") surface stabilizer adsorbed to the surface of the drug. Because of the stability of PEG-lipids, drug/PEG-lipid nanoparticulate compositions afford enhanced blood pool residence times, decreased toxicity, and increased stability of an administered drug

[0025] Another aspect of the invention is directed to pharmaceutical compositions comprising a nanoparticulate composition of the invention. The pharmaceutical composition preferably comprises a poorly soluble drug, at least one

30 PEG-phospholipid, PEG-cholesterol, PEG-vitamin A, or PEG-vitamin E surface stabilizer for a time and under conditions sufficient to provide a nanoparticle/PEG-lipid composition. The PEG-lipid surface stabilizers can be contacted with the drug either before, during, or after size reduction of the drug.

[0026] The present invention is further directed to a method of treatment comprising administering to a mammal in need a therapeutically effective amount of a nanoparticulate drug/PEG-lipid composition according to the invention.

35 [0027] Both the foregoing general description and the following detailed description are exemplary and explanatory and are intended to provide further explanation of the invention as claimed. Other objects, advantages, and novel features will be readily apparent to those skilled in the art from the following detailed description of the invention.

40 BRIEF DESCRIPTION OF THE FIGURES

[0028]

Figure 1a: Shows a photomicrograph of a composition of 2% Compound A and 0.5% albumin following milling;

45 Figure 1b: Shows a photomicrograph of a composition of 2% Compound A and 1.0% Chremophor EL following milling;

Figure 1c: Shows a photomicrograph of a composition of 2% Compound A and 1.0% F108 following milling;

50 Figure 1d: Shows a photomicrograph of a composition of 2% Compound A and 1.0% F108 in dextrose following milling;

Figure 2a: Shows a photomicrograph of a composition of 2% Compound A, 1.0% F108, and 0.005% DOSS following milling;

55 Figure 2b: Shows a photomicrograph of a composition of 2% Compound A and 1.0% F108 in saline following milling;

Figure 2c: Shows a photomicrograph of a composition of 2% Compound A and 1.0% HPC-SL following milling;

- Figure 2d: Shows a photomicrograph of a composition of 2% Compound A and 1.0% tyloxapol following milling;
- Figure 3a: Shows a photomicrograph of a composition of 2% Compound A and 1.0% vitamin E PEG following milling;
- 5 Figure 3b: Shows a photomicrograph of a composition of 2% Compound A and 1.0% PEG-5000 phospholipid in saline following milling;
- Figure 3c: Shows a photomicrograph of a composition of 2% Compound A and 1.0% PVP C-15 following milling;
- 10 Figure 3d: Shows a photomicrograph of a composition of 2% Compound A and 2.0% Tween 80 following milling;
- Figure 4: Shows a photomicrograph of a stable nanoparticulate composition of 2% Compound A and 1.0% PEG-5000 phospholipid following milling;
- 15 Figure 5: Shows a Horiba particle size analysis of a milled mixture of 2% Compound B and 2% Plurionic F68™;
- Figure 6: Shows a Horiba particle size analysis of a milled mixture of 2% Compound B and 2% Plurionic F88™;
- Figure 7: Shows a Horiba particle size analysis of a milled mixture of 1% Compound B and 1% Plurionic F108™;
- 20 Figure 8: Shows a Horiba particle size analysis of a milled mixture of 1% Compound B and 0.25% Chremophor EL™;
- Figure 9: Shows a Horiba particle size analysis of a milled mixture of 1% Compound B and 0.25% Tween 80™;
- 25 Figure 10: Shows a photomicrograph of a composition of 2% Compound B and 2% Tyloxapol following milling; and
- Figure 11: Shows a Horiba particle size analysis of a milled mixture of 2% Compound B and 1% PEG-5000 Phospholipid.

DETAILED DESCRIPTION OF THE INVENTION

[0029] The present invention is directed to a composition comprising nanoparticulate drug having at least one PEG-phospholipid, PEG-cholesterol, PEG-cholesterol derivative, PEG-vitamin A, or PEG-vitamin E surface stabilizer adsorbed on the surface thereof, and methods of making and using such nanoparticulate compositions.

A. Compositions

[0030] The compositions of the invention comprise nanoparticulate drug and at least one PEG-phospholipid, PEG-cholesterol, PEG-cholesterol derivative, PEG-vitamin A, or PEG-vitamin E surface stabilizer adsorbed to the surface of the drug. Surface stabilizers useful herein physically adhere to the surface of the nanoparticulate drug, but do not chemically react with the drug or itself. Individually adsorbed molecules of the surface stabilizer are essentially free of intermolecular cross-linkages.

[0031] The present invention also includes nanoparticulate compositions having at least one PEG-phospholipid, PEG-cholesterol, PEG-cholesterol derivative, PEG-vitamin A, or PEG-vitamin E surface stabilizer adsorbed on the surface thereof, formulated into compositions together with one or more non-toxic physiologically acceptable carriers, adjuvants, or vehicles, collectively referred to as carriers. The compositions can be formulated for parenteral injection, oral administration in solid or liquid form, rectal or topical administration, and the like.

1. Drug Particles

[0032] The nanoparticles of the invention comprise a therapeutic or diagnostic agent, collectively referred to as a "drug." A therapeutic agent can be a pharmaceutical agent, including biologics such as proteins, peptides, and nucleotides, or a diagnostic agent, such as a contrast agent, including x-ray contrast agents. The drug exists either as a discrete, crystalline phase, or as an amorphous phase. The crystalline phase differs from a non-crystalline or amorphous phase which results from precipitation techniques, such as those described in EP Patent No. 275,796.

[0033] The invention can be practiced with a wide variety of drugs. The drug is preferably present in an essentially pure form, is poorly soluble, and is dispersible in at least one liquid medium. By "poorly soluble" it is meant that the

drug has a solubility in the liquid dispersion medium of less than about 10 mg/mL, and preferably of less than about 1 mg/mL.

[0034] The drug can be selected from a variety of known classes of drugs, including, for example, proteins, peptides, nucleotides, anti-obesity drugs, nutraceuticals, corticosteroids, elastase inhibitors, analgesics, anti-fungals, oncology therapies, anti-emetics, analgesics, cardiovascular agents, anti-inflammatory agents, anthelmintics, anti-arrhythmic agents, antibiotics (including penicillins), anticoagulants, antidepressants, antidiabetic agents, antiepileptics, antihistamines, antihypertensive agents, antimuscarinic agents, antimycobacterial agents, antineoplastic agents, immunosuppressants, antithyroid agents, antiviral agents, anxiolytic sedatives (hypnotics and neuroleptics), astringents, beta-adrenoceptor blocking agents, blood products and substitutes, cardiac inotropic agents, contrast media, corticosteroids, cough suppressants (expectorants and mucolytics), diagnostic agents, diagnostic imaging agents, diuretics, dopaminergics (antiparkinsonian agents), haemostatics, immuriological agents, lipid regulating agents, muscle relaxants, parasympathomimetics, parathyroid calcitonin and biphosphonates, prostaglandins, radiopharmaceuticals, sex hormones (including steroids), anti-allergic agents, stimulants and anoretics, sympathomimetics, thyroid agents, vasodilators and xanthines.

[0035] A description of these classes of drugs and a listing of species within each class can be found in Martindale, *The Extra Pharmacopoeia*, Twenty-ninth Edition (The Pharmaceutical Press, London, 1989). The drugs are commercially available and/or can be prepared by techniques known in the art.

2. PEG-lipid Surface Stabilizers

[0036] Suitable PEG-lipid surface stabilizers are selected from any PEG-phospholipid, PEG-cholesterol, PEG-cholesterol derivative, PEG-vitamin A, or PEG-vitamin E.

[0037] The molecular weight of the PEG substituent on the lipid affects the circulation half life of the compound. Derivatized lipids having a PEG of high molecular mass, such as about 4000 to about 5000 Da, have long circulation half lives, with lower molecular weights of 2000 Da also being useful. Derivatized lipids having lower PEG molecular masses, such as about 750 to about 800 Da are also useful, although the circulation half-life begins to be compromised at this lower molecular weight. Allen at 218; and Yuda et al. at 1349.

[0038] Liposomes containing PEG-derivatives and having functional groups at their terminals, such as DPP-PEG-OH and DSPE-PEG-COOH (e.g., α -(dipalmitoylphosphatidyl)- ω -hydroxypolyoxyethylene and distearoylphosphatidyl-N-(3-carboxypropionyl polyoxyethylene succinyl)ethanolamine), also lengthen the circulation half-life of the compounds as compared to non-PEG derivatized compounds and PEG-derivatized compounds of the same molecular weight lacking the functional end group. Yuda et al. at 1349. Moreover, PEG-derivatized compounds having terminal end functional groups and lower molecular weights, e.g., about 1000 Da or less, result in longer circulation times as compared to non-PEG derivatized compounds and PEG-derivatized compounds of the same molecular weight lacking the functional end group.

[0039] Two exemplary commercially available PEG-liposomes are PEG-5000™ and PEG-2000™ (Shearwater Polymers, Inc.).

[0040] Two or more surface stabilizers can be used in combination.

3. Auxiliary Surface Stabilizers

[0041] The compositions of the invention can also include one or more auxiliary surface stabilizers in addition to the at least one PEG-lipid surface stabilizer. Suitable auxiliary surface stabilizers can preferably be selected from known organic and inorganic pharmaceutical excipients. Such excipients include various polymers, low molecular weight oligomers, natural products, and surfactants. Preferred surface stabilizers include nonionic and ionic surfactants. Two or more surface auxiliary stabilizers can be used in combination.

[0042] Representative examples of auxiliary surface stabilizers include cetyl pyridinium chloride, gelatin, casein, lecithin (phosphatides), dextran, glycerol, gum acacia, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glycerol monostearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers (e.g., macrogol ethers such as cetomacrogol 1000), polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters (e.g., the commercially available Tweens® such as e.g., Tween 20® and Tween 80® (ICI Specialty Chemicals)); polyethylene glycols (e.g., Carbowax 3350® and 1450®, and Carbopol 934® (Union Carbide)), dodecyl trimethyl ammonium bromide, polyoxyethylene stearates, colloidal silicon dioxide, phosphates, sodium dodecylsulfate, carboxymethylcellulose calcium, hydroxypropyl celluloses (e.g., HPC, HPC-SL, and HPC-L), hydroxypropyl methylcellulose (HPMC), carboxymethylcellulose sodium, methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethyl-cellulose phthalate, noncrystalline cellulose, magnesium aluminum silicate, triethanolamine, polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), 4-(1,1,3,3-tetramethylbutyl)-phenol polymer with ethylene oxide and formaldehyde (also known as tyloxapol, superione, and triton), poloxamers (e.g., Pluronic F68®).

and F108®, which are block copolymers of ethylene oxide and propylene oxide); poloxamines (e.g., Tetronic 908®, also known as Poloxamine 908®, which is a tetrafunctional block copolymer derived from sequential addition of propylene oxide and ethylene oxide to ethylenediamine (BASF Wyandotte Corporation, Parsippany, N.J.)); a charged phospholipid such as dimyristoyl phosphatidyl glycerol, dioctylsulfosuccinate (DOSS); Tetronic 1508® (T-1508) (BASF Wyandotte Corporation), dialkylesters of sodium sulfosuccinic acid (e.g., Aerosol OT®, which is a dioctyl ester of sodium sulfosuccinic acid (American Cyanamid)); Duponol P®, which is a sodium lauryl sulfate (DuPont); Tritons X-200®, which is an alkyl aryl polyether sulfonate (Rohm and Haas); Crodestas F-110®, which is a mixture of sucrose stearate and sucrose distearate (Croda Inc.); p-isononylphenoxypoly-(glycidol), also known as Olin-LOG® or Surfactant 10-G® (Olin Chemicals, Stamford, CT); Crodestas SL-40® (Croda, Inc.); decanoyl-N-methylglucamide; n-decyl β -D-glucopyranoside; n-decyl β -D-maltopyranoside; n-dodecyl β -D-glucopyranoside; n-dodecyl β -D-maltoside; heptanoyl-N-methylglucamide; n-heptyl- β -D-glucopyranoside; n-heptyl β -D-thioglucoside; n-hexyl β -D-glucopyranoside; nonanoyl-N-methylglucamide; n-nonyl β -D-glucopyranoside; octanoyl-N-methylglucamide; n-octyl- β -D-glucopyranoside; octyl β -D-thioglucopyranoside; and the like.

[0043] Most of these surface stabilizers are known pharmaceutical excipients and are described in detail in the *Handbook of Pharmaceutical Excipients*, published jointly by the American Pharmaceutical Association and The Pharmaceutical Society of Great Britain (The Pharmaceutical Press, 1986). The surface stabilizers are commercially available and/or can be prepared by techniques known in the art.

3. Nanoparticulate Drug/PEG-Lipid Particle Size

[0044] Preferably, the compositions of the invention contain nanoparticles which have an effective average particle size of less than about 1000 nm (i.e., 1 micron), more preferably less than about 600 nm, less than about 400 nm, less than about 300 nm, less than about 250 nm, less than about 100 nm, or less than about 50 nm, as measured by light-scattering methods, microscopy, or other appropriate methods. By "an effective average particle size of less than about 1000 nm" it is meant that at least 50% of the drug particles have a weight average particle size of less than about 1000 nm when measured by light scattering techniques. Preferably, at least 70% of the drug particles have an average particle size of less than about 1000 nm, more preferably at least 90% of the drug particles have an average particle size of less than about 1000 nm, and even more preferably at least about 95% of the particles have a weight average particle size of less than about 1000 nm.

4. Concentration of Nanoparticulate Drug and Stabilizer

[0045] The relative amount of drug and one or more surface stabilizers can vary widely. The optimal amount of the surface stabilizers can depend, for example, upon the particular active agent selected, the hydrophilic lipophilic balance (HLB), melting point, and water solubility of the PEG-lipid surface stabilizer, and the surface tension of water solutions of the stabilizer, etc.

[0046] The concentration of the one or more surface stabilizers can vary from about 0.1 to about 90%, and preferably is from about 1 to about 75%, more preferably from about 10 to about 60%, and most preferably from about 10 to about 30% by weight based on the total combined weight of the drug substance and surface stabilizer.

[0047] The concentration of the drug can vary from about 99.9% to about 10%, and preferably is from about 99% to about 25%, more preferably from about 90% to about 40%, and most preferably from about 90% to about 70% by weight based on the total combined weight of the drug substance and surface stabilizer.

B. Methods of Making Nanoparticulate Formulations

[0048] The nanoparticulate drug compositions can be made using, for example, milling or precipitation techniques. Exemplary methods of making nanoparticulate compositions are described in the '684 patent.

1. Milling to obtain Nanoparticulate Drug Dispersions

[0049] Milling of aqueous drug to obtain a nanoparticulate dispersion comprises dispersing drug particles in a liquid dispersion medium, followed by applying mechanical means in the presence of grinding media to reduce the particle size of the drug to the desired effective average particle size. The particles can be reduced in size in the presence of at least one PEG-phospholipid, PEG-cholesterol, PEG-cholesterol derivative, PEG-vitamin A, or PEG-vitamin E surface stabilizer. Alternatively, the particles can be contacted with one or more surface stabilizers after attrition. Other compounds, such as a diluent, can be added to the drug/surface stabilizer composition during the size reduction process. Dispersions can be manufactured continuously or in a batch mode. The resultant nanoparticulate drug dispersion can be utilized in solid or liquid dosage formulations.

2. Precipitation to Obtain Nanoparticulate Drug Compositions

[0050] Another method of forming the desired nanoparticulate composition is by microprecipitation. This is a method of preparing stable dispersions of drugs in the presence of one or more surface stabilizers and one or more colloid stability enhancing surface active agents free of any trace toxic solvents or solubilized heavy metal impurities. Such a method comprises, for example: (1) dissolving the drug in a suitable solvent; (2) adding the formulation from step (1) to a solution comprising at least one surface stabilizer to form a clear solution; and (3) precipitating the formulation from step (2) using an appropriate non-solvent. The method can be followed by removal of any formed salt, if present, by dialysis or diafiltration and concentration of the dispersion by conventional means. The resultant nanoparticulate drug dispersion can be utilized in solid or liquid dosage formulations.

C. Methods of Using Nanoparticulate Drug Formulations Comprising One or More Surface Stabilizers

[0051] The nanoparticulate compositions of the present invention can be administered to humans and animals either orally, rectally, parenterally (intravenous, intramuscular, or subcutaneous), intracisternally, intravaginally, intraperitoneally, locally (powders, ointments or drops), or as a buccal or nasal spray.

[0052] Compositions suitable for parenteral injection may comprise physiologically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions and sterile powders for reconstitution into sterile injectable solutions or dispersions. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents, or vehicles including water, ethanol, polyols (propyleneglycol, polyethyleneglycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

[0053] The nanoparticulate compositions may also contain adjuvants such as preserving, wetting, emulsifying, and dispensing agents. Prevention of the growth of microorganisms can be ensured by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, such as aluminum monostearate and gelatin.

[0054] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is admixed with at least one of the following: (a) one or more inert excipients (or carrier), such as sodium citrate or dicalcium phosphate; (b) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and silicic acid; (c) binders, such as carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and acacia; (d) humectants, such as glycerol; (e) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (f) solution retarders, such as paraffin; (g) absorption accelerators, such as quaternary ammonium compounds; (h) wetting agents, such as cetyl alcohol and glycerol monostearate; (i) adsorbents, such as kaolin and bentonite; and (j) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. For capsules, tablets, and pills, the dosage forms may also comprise buffering agents.

[0055] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs. In addition to the active compounds, the liquid dosage forms may comprise inert diluents commonly used in the art, such as water or other solvents, solubilizing agents, and emulsifiers. Exemplary emulsifiers are ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1,3-butyleneglycol, dimethylformamide, oils, such as cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil, and sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethyleneglycols, fatty acid esters of sorbitan, or mixtures of these substances, and the like.

[0056] Besides such inert diluents, the composition can also include adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

[0057] Actual dosage levels of active ingredients in the nanoparticulate compositions of the invention may be varied to obtain an amount of active ingredient that is effective to obtain a desired therapeutic response for a particular composition and method of administration. The selected dosage level therefore depends upon the desired therapeutic effect, the route of administration, the potency of the administered drug, the desired duration of treatment, and other factors.

[0058] The total daily dose of the compounds of this invention administered to a host in single or divided dose may be in amounts of, for example, from about 1 nanomol to about 5 micromoles per kilogram of body weight. Dosage unit compositions may contain such amounts of such submultiples thereof as may be used to make up the daily dose. It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the body weight, general health, sex, diet, time and route of administration, potency of the administered drug, rates of absorption and excretion, combination with other drugs and the severity of the particular disease being treated.

[0059] The following examples are given to illustrate the present invention. It should be understood, however, that the invention is not to be limited to the specific conditions or details described in these examples.

Example 1

[0060] The purpose of this example was to test the effectiveness of different conventional intravenous surface stabilizers in producing a stable non-agglomerated nanoparticulate composition of Compound A, a poorly water-soluble compound having therapeutic activity.

[0061] All of the following formulations (except for the formulation of Pluronic F108™ and 0.005% DOSS) were prepared for roller milling in a 15 ml amber colored bottle filled with 7.5 ml of 0.8 mm YTZ Zirconia media on a U.S. Stoneware mill.

[0062] The Pluronic F108™, HPC-SL, tyloxapol, and PVP formulations were milled for 7 days; the albumin, PEG-vitamin E, Pluronic F108™ in saline, PEG-5000 phospholipid in saline, and Chremophor EL™ formulations were milled for 5 days; the Tween 80™ formulation was milled for 4 days; and the Pluronic F108™ in dextrose formulation was milled for 8 days. The formulation of Pluronic F108™ and 0.005% DOSS was DC milled rather than roller milled (DC milling is higher energy than roller milling) in a 15 ml polycarbonate tube with 4 ml of 0.5 mm SDy-20 polymeric media for 22 hours.

[0063] The figures referenced for each composition show a photomicrograph of the composition following milling.

- (a) a mixture of 2% Compound A and 0.5% albumin (Figure 1a);
- (b) a mixture of 2% Compound A and 1.0% Chremophor EL™ (polyoxyethylated castor oil; BASF Corp.) (Figure 1b);
- (c) a mixture of 2% Compound A and 1.0% Pluronic F108™ (a polyoxyethylene-polyoxypropylene copolymer; BASF Corp.) (Figure 1c);
- (d) a mixture of 2% Compound A and 1.0% Pluronic F108™ in dextrose (Figure 1d);
- (e) a mixture of 2% Compound A, 1.0% Pluronic F108™, and 0.005% DOSS (dioctyl sulfosuccinate; Aldrich Chemicals, Inc.) (Figure 2a);
- (f) a mixture of 2% Compound A and 1.0% Pluronic F108™ in saline (Figure 2b);
- (g) a mixture of 2% Compound A and 1.0% hydroxypropyl cellulose (HPC-SL; Nisso Chemical) (Figure 2c);
- (h) a mixture of 2% Compound A and 1.0% tyloxapol (Nycomed) (Figure 2d);
- (i) a mixture of 2% Compound A and 1.0% vitamin E PEG (vitamin E polyethylene glycol; Eastman Chemical, Rochester, NY) (Figure 3a);
- (j) a mixture of 2% Compound A and 1.0% PEG-5000 phospholipid (Shearwater Polymers, Inc) in saline (Figure 3b);
- (k) a mixture of 2% Compound A and 1.0% Plasdane C-15™ (polyvinylpyrrolidone; GAF Corp.) (Figure 3c); and
- (l) a mixture of 2% Compound A and 2.0% Tween 80™ (oleate of a polyoxyethylenated sorbitan; ICI Americas Inc., Wilmington, Del.) (Figure 3d).

[0064] As evidenced by the photomicrographs of the compositions following milling, none of the surfactants resulted in a stable non-agglomerated nanoparticulate composition of Compound A.

Example 2

[0065] The purpose of this example was to test the effectiveness of a PEG-lipid as an intravenously-acceptable surface stabilizer for nanoparticulate compositions. The active agent tested was Compound A.

[0066] A mixture of 2% Compound A and 1% PEG-5000™ phospholipid (Shearwater Polymers, Inc.) was roller milled in a 15 ml amber colored bottle filled with 7.5 ml of 0.8 mm YTZ Zirconia media on a U.S. Stoneware mill for 8 days. As shown in Figure 4, a stable nanoparticulate formulation of Compound A was produced. The final effective average particle size of the nanoparticulate dispersion was about 277 nm, with a standard deviation of about 87 nm. In addition, the resultant nanoparticulate formulation was stable over an extended period of time, *i.e.*, for at least one week at room temperature.

Example 3

[0067] The purpose of this example was to determine the effectiveness of various intravenous (IV)-acceptable surface stabilizers, including PEG-lipids, for nanoparticulate compositions. The active agent used was Compound B, a poorly water-soluble pharmaceutically active compound. Compound B, which serves as a dimerizing agent capable of homodimerizing two proteins containing the FKBP domain in a variety of cellular and extracellular contexts, is intended to be used in the treatment of graft versus host disease (GvHD).

[0068] Compositions (a), (b), (d), (e), (f), and (g) below were prepared for roller milling in a 15 ml amber colored

bottle filled with 7.5 ml of 0.8 mm YTZ Zirconia media on a U.S. Stoneware mill. The compositions were milled for the following time periods: (a) 132 hours; (b) 2 weeks; (d) 86 hours; (e) 86 hours; (f) 74 hours; and (g) 127 hours. Compositions (c) and (h) were prepared using the higher energy DC mill in a 15 ml polycarbonate tube filled with 4 ml of 0.5 mm polymeric media. Compositions (c) and (h) were milled for 24 and 20 hours, respectively.

5 [0069] The figures referenced for each composition show a Horiba particle size distribution profile or a micrograph (optical microscopy) of the milled composition.

- (a) a mixture of 2% Compound B and 2% Plurionic F68™ (a polyoxyethylene propylene glycol monofatty acid ester; BASF Corp.) (Figure 5);
- 10 (b) a mixture of 2% Compound B and 2% Plurionic F88™ (a polyoxyethylene-polyoxypropylene copolymer; BASF Corp.) (Figure 6);
- (c) a mixture of 1% Compound B and 1% Plurionic F108™ (BASF Corp.) (Figure 7);
- (d) a mixture of 1% Compound B and 0.25% Chremophor EL™ (Figure 8);
- (e) a mixture of 1% Compound B and 0.25% Tween 80™ (Figure 9);
- 15 (f) a mixture of 2% Compound B and 1% PVP C-15; this composition solubilized and, therefore, a colloidal suspension was not formed;
- (g) a mixture of 2% Compound B and 2% tyloxapol; this composition formed large particles (Figure 10); and
- (h) a mixture of 2% AP1903 and 1% PEG-5000 Phospholipid (Figure 11).

20 [0070] Figures 5-10 show that the use of Plurionic F68™, Plurionic F88™, Plurionic F108™, Cremophor EL™, Tween 80™, and tyloxapol, produced heterogeneous dispersions, with particle sizes ranging from 1 micron (1000 nm) to 10 microns. Moreover, the minimum particle size obtained was between 300 to 350 nm. In addition, an aggressive milling period was required to obtain small particle sizes with these surface stabilizers.

25 [0071] In contrast, the use of a PEG-lipid surface stabilizer enabled a shorter milling period and produced a well-dispersed colloidal suspension having a maximum particle size of less than about 195 nm. See e.g., Figure 11.

Claims

30 1. A nanoparticulate composition comprising:

- (a) an organic drug having an effective average particle size of less than 1000 nm; and
- (b) at least one polyethylene glycol-derivatized lipid (PEG-lipid) selected from the group consisting of a PEG-phospholipid, PEG-cholesterol, PEG-cholesterol derivative, PEG-vitamin A, and PEG-vitamin E,

35 wherein the PEG-lipid is adsorbed on the surface of the drug in an amount sufficient to maintain the effective average particle size of less than 1000 nm.

40 2. The composition of claim 1, wherein the drug is present in an amount of 99.9 to 10% (w/w), based on the total combined weight of the drug and surface stabilizer.

3. The composition of claims 1 or 2, wherein the at least one PEG-lipid is present in an amount of 0.1 to 90% (w/w).

45 4. The composition of any preceding claim, wherein the drug is selected from the group consisting of a crystalline phase drug and an amorphous phase drug.

5. The composition of any preceding claim, further comprising at least one surface stabilizer which is not a PEG-phospholipid, PEG-cholesterol, PEG-cholesterol derivative, PEG-vitamin A, or PEG-vitamin E.

50 6. The composition of any preceding claim, comprising two or more PEG-lipids selected from the group consisting of PEG-phospholipid, PEG-cholesterol, PEG-cholesterol derivative, PEG-vitamin A, and PEG-vitamin E.

55 7. The composition of any preceding claim, wherein the effective average particle size of the nanoparticulate composition is selected from the group consisting of less than 600 nm, less than 400 nm, less than 300 nm, less than 200 nm, less than 100 nm, and less than 50 nm.

8. An injectable formulation comprising the composition of any preceding claim.

9. A method of making a nanoparticulate composition comprising an organic drug having an average particle size of less than 1000 nm and having at least one polyethylene glycol-derivatized lipid (PEG-lipid) adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than 1000 nm,
said method comprising contacting said drug with at least one PEG-lipid for a time and under conditions
5 sufficient to provide a nanoparticle/PEG-lipid composition, wherein the PEG-lipid is selected from the group consisting of a PEG-phospholipid, PEG-cholesterol, PEG-cholesterol derivative, PEG-vitamin A, and PEG-vitamin E.
10. The method of claim 9, wherein the drug is present in an amount of 99.9 to 10% (w/w), based on the total combined weight of the drug and surface stabilizer.
11. The method of claims 9 or 10, wherein the at least one PEG-lipid is present in an amount of 0.1 to 90% (w/w).
12. The method of any one of claims 9 to 11, wherein the drug is selected from the group consisting of a crystalline phase drug and an amorphous phase drug.
13. The method of any one of claims 9 to 12, further comprising at least one surface stabilizer which is not a PEG-phospholipid, PEG-cholesterol, PEG-cholesterol derivative, PEG-vitamin A, or PEG-vitamin E.
14. The method of any one of claims 9 to 13, comprising two or more PEG-lipids selected from the group consisting of PEG-phospholipid, PEG-cholesterol, PEG-cholesterol derivative, PEG-vitamin A, and PEG-vitamin E.
15. The method of any one of claims 9 to 14, wherein the effective average particle size of the nanoparticulate composition is selected from the group consisting of less than 600 nm, less than 400 nm, less than 300 nm, less than 200 nm, less than 100 nm, and less than 50 nm.
16. A nanoparticulate composition according to any one of claims 1 to 7 or an injectable formulation according to claim 8 for use as a medicament.
17. A method of making a nanoparticulate composition, wherein the nanoparticulate composition comprises an organic drug having at least one polyethylene glycol-derivatized lipid (PEG-lipid) adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than 1000 nm,
said method comprising
35 (a) dissolving the drug in a solvent;
(b) adding the solubilized drug to a solution comprising at least one PEG-lipid to form a clear solution;
(c) precipitating the solubilized drug having a PEG-lipid as a surface stabilizer using a non-solvent, wherein the PEG-lipid is selected from the group consisting of a PEG-phospholipid, PEG-cholesterol, PEG-cholesterol derivative, PEG-vitamin A, and PEG-vitamin E,
40 wherein said method produces a nanoparticulate composition having at least one PEG-lipid as a surface stabilizer and an effective average particle size of less than 1000 nm.
18. The method of claim 17, wherein the drug is present in an amount of 99.9 to 10% (w/w), based on the total combined weight of the drug and surface stabilizer.
19. The method of claims 17 or 18, wherein the at least one PEG-lipid is present in an amount of 0.1 to 90% (w/w).
20. The method of any one of claims 17 to 19, wherein the drug is selected from the group consisting of a crystalline phase drug and an amorphous phase drug.
21. The method of any one of claims 17 to 20, further comprising at least one surface stabilizer which is not a PEG-phospholipid, PEG-cholesterol, PEG-cholesterol derivative, PEG-vitamin A, or PEG-vitamin E.
22. The method of any one of claims 17 to 21, comprising two or more PEG-lipids selected from the group consisting of PEG-phospholipid, PEG-cholesterol, PEG-cholesterol derivative, PEG-vitamin A, and PEG-vitamin E.
23. The method of any one of claims 17 to 22, wherein the effective average particle size of the nanoparticulate composition is selected from the group consisting of less than 600 nm, less than 400 nm, less than 300 nm, less than

200 nm, less than 100 nm, and less than 50 nm.

Patentansprüche

5

1. Eine nanopartikuläre Zusammensetzung, welche:

10

- a) einen organischen Wirkstoff mit einer effektiven durchschnittlichen Partikelgröße von weniger als 1000 nm; und
- b) mindestens ein Polyethylenglycol-derivatisiertes Lipid (PEG-Lipid), ausgewählt aus der Gruppe bestehend aus einem PEG-Phospholipid, PEG-Cholesterol, PEG-Cholesterolderivat, PEG-Vitamin A und PEG-Vitamin E,

umfasst, wobei das PEG-Lipid in einer Menge an der Oberfläche des Wirkstoffs adsorbiert ist, die ausreicht, um eine effektive durchschnittliche Partikelgröße von weniger als 1000 nm aufrechtzuerhalten.

15

2. Zusammensetzung gemäß Anspruch 1, wobei der Wirkstoff in einer Menge von 99,9 bis 10 % (Gewichts-%), bezogen auf das Gesamtgewicht von Wirkstoff und Oberflächenstabilisator, vorliegt.

20

3. Zusammensetzung gemäß Anspruch 1 oder 2, wobei das mindestens eine PEG-Lipid in einer Menge von 0,1 bis 90 % (Gewichts-%) vorliegt.

4. Zusammensetzung gemäß einem der vorherigen Ansprüche, wobei der Wirkstoff ausgewählt ist aus der Gruppe bestehend aus einem Wirkstoff kristallinischer Phase und einem Wirkstoff amorpher Phase.

25

5. Zusammensetzung gemäß einem der vorherigen Ansprüche, welche zusätzlich mindestens einen Oberflächenstabilisator umfasst, der kein PEG-Phospholipid, PEG-Cholesterol, PEG-Cholesterolderivat, PEG-Vitamin A oder PEG-Vitamin E ist.

30

6. Zusammensetzung gemäß einem der vorherigen Ansprüche, welche zwei oder mehr PEG-Lipide umfasst, die aus der Gruppe bestehend aus PEG-Phospholipid, PEG-Cholesterol, PEG-Cholesterolderivat, PEG-Vitamin A und PEG-Vitamin E ausgewählt sind.

35

7. Zusammensetzung gemäß einem der vorherigen Ansprüche, wobei die effektive durchschnittliche Partikelgröße der nanopartikulären Zusammensetzung ausgewählt ist aus der Gruppe bestehend aus weniger als 600 nm, weniger als 400 nm, weniger als 300 nm, weniger als 200 nm, weniger als 100 nm, und weniger als 50 nm.

8. Eine injizierbare Formulierung, welche die Zusammensetzung eines der vorhergehenden Ansprüche umfasst.

40

9. Verfahren zur Herstellung einer nanopartikulären Zusammensetzung, welche einen organischen Wirkstoff mit einer durchschnittlichen Partikelgröße von weniger als 1000 nm umfasst, der an seiner Oberfläche mindestens ein Polyethylenglycol-derivatisiertes Lipid (PEG-Lipid) in ausreichender Menge adsorbiert hat, um eine effektive Partikelgröße von weniger als 1000 nm aufrechtzuerhalten,

45

wobei das genannte Verfahren das Kontaktieren des genannten Wirkstoffes mit mindestens einem PEG-Lipid für eine Zeit und unter Bedingungen umfasst, die ausreichend sind, um eine Nanopartikel/PEG-Lipid-Zusammensetzung bereitzustellen, wobei das PEG-Lipid ausgewählt ist aus der Gruppe bestehend aus PEG-Phospholipid, PEG-Cholesterol, PEG-Cholesterolderivat, PEG-Vitamin A und PEG-Vitamin E.

50

10. Verfahren gemäß Anspruch 9, wobei der Wirkstoff in einer Menge von 99,9 bis 10 % (Gewichts-%), bezogen auf das Gesamtgewicht von Wirkstoff und Oberflächenstabilisator, vorliegt.

11. Verfahren gemäß Anspruch 9 oder 10, wobei das mindestens eine PEG-Lipid in einer Menge von 0,1 bis 90 % (Gewichts-%) vorliegt.

55

12. Verfahren gemäß einem der Ansprüche 9 bis 11, wobei der Wirkstoff ausgewählt ist aus der Gruppe bestehend aus einem Wirkstoff kristallinischer Phase und einem Wirkstoff amorpher Phase.

13. Verfahren gemäß einem der Ansprüche 9 bis 12, welches zusätzlich mindestens einen Oberflächenstabilisator

umfasst, der kein PEG-Phospholipid, PEG-Cholesterol, PEG-Cholesterolderivat, PEG-Vitamin A oder PEG-Vitamin E ist.

- 5 14. Verfahren gemäß einem der Ansprüche 9 bis 13, welches zwei oder mehr PEG-Lipide umfasst, die aus der Gruppe bestehend aus PEG-Phospholipid, PEG-Cholesterol, PEG-Cholesterolderivat, PEG-Vitamin A und PEG-Vitamin E ausgewählt sind.
- 10 15. Verfahren gemäß einem der Ansprüche 9 bis 14, wobei die effektive durchschnittliche Partikelgröße der nanopartikulären Zusammensetzung ausgewählt ist aus der Gruppe bestehend aus weniger als 600 nm, weniger als 400 nm, weniger als 300 nm, weniger als 200 nm, weniger als 100 nm, und weniger als 50 nm.
16. Eine nanopartikuläre Zusammensetzung gemäß einem der Ansprüche 1 bis 7 oder eine injizierbare Formulierung gemäß Anspruch 8 zur Verwendung als Medikament.
- 15 17. Verfahren zur Herstellung einer nanopartikulären Zusammensetzung, wobei die nanopartikuläre Zusammensetzung einen organischen Wirkstoff umfasst, der an seiner Oberfläche mindestens ein Polyethylenglycol-derivatisiertes Lipid (PEG-Lipid) in einer Menge adsorbiert hat, die ausreicht, um eine effektive durchschnittliche Partikelgröße von weniger als 1000 nm aufrechtzuerhalten, wobei das genannte Verfahren
 - 20 a) das Auflösen des Wirkstoffes in einem Lösungsmittel;
 - b) die Zugabe des gelösten Wirkstoffes zu einer Lösung, welche mindestens ein PEG-Lipid umfasst, unter Bildung einer klaren Lösung;
 - c) das Ausfällen des gelösten Wirkstoffes mit einem PEG-Lipid als Oberflächenstabilisator unter Verwendung eines Nicht-Lösungsmittels, wobei das PEG-Lipid ausgewählt ist aus der Gruppe bestehend aus PEG-Phospholipid, PEG-Cholesterol, PEG-Cholesterolderivat, PEG-Vitamin A und PEG-Vitamin E;

umfasst, wobei das genannte Verfahren eine nanopartikuläre Zusammensetzung mit mindestens einem PEG-Lipid als Oberflächenstabilisator und einer effektiven durchschnittlichen Partikelgröße von weniger als 1000 nm produziert.
- 30 18. Verfahren gemäß Anspruch 17, wobei der Wirkstoff in einer Menge von 99,9 bis 10 % (Gewichts-%), bezogen auf das Gesamtgewicht von Wirkstoff und Oberflächenstabilisator, vorliegt.
- 35 19. Verfahren gemäß Anspruch 17 oder 18, wobei das mindestens eine PEG-Lipid in einer Menge von 0,1 bis 90 % (Gewichts-%) vorliegt.
20. Verfahren gemäß einem der Ansprüche 17 bis 19, wobei der Wirkstoff ausgewählt ist aus der Gruppe bestehend aus einem Wirkstoff kristallinischer Phase und einem Wirkstoff amorpher Phase.
- 40 21. Verfahren gemäß einem der Ansprüche 17 bis 20, welches zusätzlich mindestens einen Oberflächenstabilisator umfasst, der kein PEG-Phospholipid, PEG-Cholesterol, PEG-Cholesterolderivat, PEG-Vitamin A oder PEG-Vitamin E ist.
- 45 22. Verfahren gemäß einem der Ansprüche 17 bis 21, welches zwei oder mehr PEG-Lipide umfasst, die aus der Gruppe bestehend aus PEG-Phospholipid, PEG-Cholesterol, PEG-Cholesterolderivat, PEG-Vitamin A und PEG-Vitamin E ausgewählt sind.
- 50 23. Verfahren gemäß einem der Ansprüche 17 bis 22, wobei die effektive durchschnittliche Partikelgröße der nanopartikulären Zusammensetzung ausgewählt ist aus der Gruppe bestehend aus weniger als 600 nm, weniger als 400 nm, weniger als 300 nm, weniger als 200 nm, weniger als 100 nm, und weniger als 50 nm.

Revendications

- 55 1. Composition de nanoparticules, comprenant :
 - (a) un médicament organique ayant un diamètre moyen effectif de particules inférieur à 1000 nm ; et
 - (b) au moins un polyéthylène-glycol lipide dérivé (PEG-lipide), choisi dans le groupe consistant en un PEG-

phospholipide, un PEG-cholestérol, un dérivé de PEG-cholestérol, un PEG-vitamine A et un PEG-vitamine E,

dans laquelle le PEG-lipide est adsorbé sur la surface du médicament en une quantité suffisante pour maintenir le diamètre effectif de particules à une valeur inférieure à 1000 nm.

5

2. Composition suivant la revendication 1, dans laquelle le médicament est présent en une quantité de 99,9 à 10 % (en poids/poids), sur la base du poids combiné total du médicament et du stabilisant de surface.

10

3. Composition suivant la revendication 1 ou 2, dans laquelle ledit au moins un PEG-lipide est présent en une quantité de 0,1 à 90 % (en poids/poids).

4. Composition suivant l'une quelconque des revendications précédentes, dans laquelle le médicament est choisi dans le groupe consistant en un médicament en phase cristalline et un médicament en phase amorphe.

15

5. Composition suivant l'une quelconque des revendications précédentes, comprenant en outre au moins un stabilisant de surface qui n'est pas un PEG-phospholipide, un PEG-cholestérol, un dérivé de PEG-cholestérol, un PEG-vitamine A et un PEG-vitamine E.

20

6. Composition suivant l'une quelconque des revendications précédentes, comprenant deux ou plus de deux PEG-lipides choisis dans le groupe consistant en PEG-phospholipide, PEG-cholestérol, dérivé de PEG-cholestérol, PEG-vitamine A et PEG-vitamine E.

25

7. Composition suivant l'une quelconque des revendications précédentes, dans laquelle le diamètre moyen effectif de particules de la composition de nanoparticules est choisi dans le groupe consistant en une valeur inférieure à 600 nm, une valeur inférieure à 400 nm, une valeur inférieure à 300 nm; une valeur inférieure à 200 nm, une valeur inférieure à 100 nm et une valeur inférieure à 50 nm.

8. Formulation injectable comprenant la composition suivant l'une quelconque des revendications précédentes.

30

9. Procédé pour la préparation d'une composition de nanoparticules comprenant un médicament organique ayant un diamètre moyen de particules inférieur à 1000 nm et comprenant au moins un polyéthylène-glycol lipide dérivé (PEG-lipide) adsorbé sur sa surface en une quantité suffisante pour maintenir un diamètre moyen effectif de particules inférieur à 1000 nm,

35

ledit procédé comprenant la mise en contact dudit médicament avec au moins un PEG-lipide pendant un temps et dans des conditions suffisants pour disposer une composition de nanoparticules/PEG-lipide, ledit PEG-lipide étant choisi dans le groupe consistant en un PEG-phospholipide, un PEG-cholestérol, un dérivé de PEG-cholestérol, un PEG-vitamine A et un PEG-vitamine E.

40

10. Procédé suivant la revendication 9, dans lequel le médicament est présent en une quantité de 99,9 à 10 % (en poids/poids), sur la base du poids combiné total du médicament et du stabilisant de surface.

11. Procédé suivant la revendication 9 ou 10, dans lequel ledit au moins un PEG-lipide est présent en une quantité de 0,1 à 90 % (en poids/poids).

45

12. Procédé suivant l'une quelconque des revendications 9 à 11, dans lequel le médicament est choisi dans le groupe consistant en un médicament en phase cristalline et un médicament en phase amorphe.

50

13. Procédé suivant l'une quelconque des revendications 9 à 12, comprenant en outre au moins un stabilisant de surface qui n'est pas un PEG-phospholipide, un PEG-cholestérol, un dérivé de PEG-cholestérol, un PEG-vitamine A et un PEG-vitamine E.

55

14. Procédé suivant l'une quelconque des revendications 9 à 13, comprenant deux ou plus de deux PEG-lipides choisis dans le groupe consistant en PEG-phospholipide, PEG-cholestérol, dérivé de PEG-cholestérol, PEG-vitamine A et PEG-vitamine E.

15. Procédé suivant l'une quelconque des revendications 9 à 14, dans lequel le diamètre moyen effectif de particules de la composition de nanoparticules est choisi dans le groupe consistant en une valeur inférieure à 600 nm, une valeur inférieure à 400 nm, une valeur inférieure à 300 nm, une valeur inférieure à 200 nm, une valeur inférieure

à 100 nm et une valeur inférieure à 50 nm.

16. Composition de nanoparticules suivant l'une quelconque des revendications 1 à 7 ou formulation injectable suivant la revendication 8, destinée à être utilisée comme médicament.
- 5 17. Procédé pour la préparation d'une composition de nanoparticules, dans lequel la composition de nanoparticules comprend un médicament organique comprenant au moins un polyéthylène-glycol lipide dérivé (PEG-lipide) adsorbé sur sa surface en une quantité suffisante pour maintenir un diamètre moyen effectif de particules inférieur à 1000 nm,
10 ledit procédé comprenant les étapes consistant :

(a) à dissoudre le médicament dans un solvant ;
(b) à ajouter le médicament solubilisé à une solution comprenant au moins un PEG-lipide pour former une solution claire ;
15 (c) à précipiter le médicament solubilisé comprenant un PEG-lipide comme stabilisant de surface en utilisant un non-solvant, ledit PEG-lipide étant choisi dans le groupe consistant en un PEG-phospholipide, un PEG-cholestérol, un dérivé de PEG-cholestérol, un PEG-vitamine A et un PEG-vitamine E,

ledit procédé produisant une composition de nanoparticules comprenant au moins un PEG-lipide comme
20 stabilisant de surface et ayant un diamètre moyen effectif de particules inférieur à 1000 nm.
18. Procédé suivant la revendication 17, dans lequel le médicament est présent en une quantité de 99,9 à 10 % (en poids/poids), sur la base du poids combiné total du médicament et du stabilisant de surface.
- 25 19. Procédé suivant la revendication 17 ou 18, dans lequel ledit au moins un PEG-lipide est présent en une quantité de 0,1 à 90 % (en poids/poids).
20. Procédé suivant l'une quelconque des revendications 17 à 19, dans lequel le médicament est choisi dans le groupe consistant en un médicament en phase cristalline et un médicament en phase amorphe.
- 30 21. Procédé suivant l'une quelconque des revendications 17 à 20, comprenant en outre au moins un stabilisant de surface qui n'est pas un PEG-phospholipide, un PEG-cholestérol, un dérivé de PEG-cholestérol, un PEG-vitamine A et un PEG-vitamine E.
- 35 22. Procédé suivant l'une quelconque des revendications 17 à 21, comprenant deux ou plus de deux PEG-lipides choisis dans le groupe consistant en PEG-phospholipide, PEG-cholestérol, dérivé de PEG-cholestérol, PEG-vitamine A et PEG-vitamine E.
- 40 23. Procédé suivant l'une quelconque des revendications 17 à 22, dans lequel le diamètre moyen effectif de particules de la composition de nanoparticules est choisi dans le groupe consistant en une valeur inférieure à 600 nm, une valeur inférieure à 400 nm, une valeur inférieure à 300 nm, une valeur inférieure à 200 nm, une valeur inférieure à 100 nm et une valeur inférieure à 50 nm.

45

50

55

Figure 1a

2% Compound A + 0.5% Albumin




Figure 1b

2% Compound A + 1% Cremophor EL




Figure 1c

2% Compound A + 1% F108




Figure 1d

2% Compound A + 1% F108 in dextrose




Figure 2a

2% Compound A + 1% F108 + 0.005% DOSS



Figure 2b

2% Compound A + 1% F108 in saline



Figure 2c

2% Compound A + 1% HPC-SL




Figure 2d

2% Compound A + 1% Tyloxapol




Figure 3a

2% Compound A + 1% Vitamin E PEG




Figure 3b

2% Compound A + 1% PEG-5000 Phospholipid in saline




Figure 3d

2% Compound A + 2% Tween 80




Figure 3c

2% Compound A + 1% PVP C-15





Figure 4

2% Compound A + 1% PEG-5000 Phospholipid



BEST AVAILABLE COPY

Figure 5

2% Compound B and 2% F68

Condition
T% (He-Ne): 94.3% Dist. Form: Sig. Sampling times : 15,
(LAMP): 83.8% R.R. Index 1.20-0.101 (

Agitation : 2 Circulin : 2 U. sono : OFF(30)

Format
Dist. base : Volume Scaling : Auto Axis : LogX - LinearY

Data
Median : 9.388µm SP. Area: 23180cm²/cm² S.D. : 10.248µm
Mode : 14.174µm Mean : 11.814µm
C.V. : 88.23%

Span : (D 10.0-D 00.0) / D50 = 2.597

Dia. on % (90.0%) : 25.289µm	% on Dia. (0.400µm) : 3.3%
Dia. on % (50.0%) : 9.388µm	% on Dia. (0.300µm) : 1.4%
Dia. on % (88.0%) : 31.809µm	% on Dia. (0.200µm) : 0.2%
Dia. on % (80.0%) : 18.812µm	% on Dia. (0.100µm) : 0.0%
Dia. on % (70.0%) : 14.980µm	% on Dia. (1.000µm) : 11.0%




Figure 6
2% Compound B and 2% F88

Condition
T%(He-Ne): 99.1% Dist. Form: Std.
(LAMP): 99.1% R.F. Index: 1.20-0.101 Sampling times: 15
Agitation: 2 Circuln: 2 U.sonic: ON(30)
Format
Dist. base: Volume Scallng: Auto Axis: LogX - Linear
Data
Median: 0.401µm SP.Area: 151231cm²/cm² S.D.: 0.591µm
Mode: 0.362µm Mean: 0.596µm
C.V.: 99.14%
Span: (D 10.0-D 90.0) / D50 = 2.339

Dia. on % (90.0%) :	1.190µm	% on Dia. (0.400µm) :	49.8%
Dia. on % (50.0%) :	0.401µm	% on Dia. (0.300µm) :	21.7%
Dia. on % (95.0%) :	1.681µm	% on Dia. (0.200µm) :	3.0%
Dia. on % (80.0%) :	0.855µm	% on Dia. (0.100µm) :	0.0%
Dia. on % (70.0%) :	0.519µm	% on Dia. (1.000µm) :	87.8%





Figure 7

1% Compound B and 1% F108

Condition : 88.0%
 T%(He-Ne) : 84.1%
 (LAMP)
 Agitation : 2 Circuln : 2 U.sonic : OFF(30)
 Format : Volume Scaling : Auto Axis : LogX - Linear
 Dist.base :
 Data :
 Median : 0.317µm SP.Area: 190757cm²/cm² S.D. : 0.227µm
 Mode : 0.282µm Mean : 0.381µm
 C.V. : 59.50%
 Span : (D 10.0-D 90.0) / D50 = 1.229
 Dia. on % (90.0%) : 0.807µm % on Dia. (0.400µm) : 73.2%
 Dia. on % (50.0%) : 0.317µm % on Dia. (0.300µm) : 43.0%
 Dia. on % (95.0%) : 0.807µm % on Dia. (0.200µm) : 8.0%
 Dia. on % (80.0%) : 0.448µm % on Dia. (0.100µm) : 0.0%
 Dia. on % (70.0%) : 0.383µm % on Dia. (1.000µm) : 97.1%



BEST AVAILABLE COPY

Figure 8

1% Compound B and 0.25% Chromophor EL

Condition
T%(He-Ne): 97.4% Dist. Form: Sig
(LAMP): 93.9% R.R. Index: 1.2b-0.101 Sampling times : 15)
Agitation : 2 Circuitn : 2 U. sonlo : OFF(30)
Format
Dist. base : Volume Sealing : Auto Axis : LogX - Lineary
Data
Median : 2.328µm SP. Area: 87887cm²/cm² S.D. : 2.778µm
Mode : 4.186µm Mean : 2.892µm
C.V. : 92.83%
Span : (D 10.0-D 90.0) / D50 = 2.855
Dia. on % (90.0%) : 8.982µm % on Dia. (0.400µm) : 18.8%
Dia. on % (50.0%) : 2.328µm % on Dia. (0.300µm) : 8.6%
Dia. on % (95.0%) : 8.458µm % on Dia. (0.200µm) : 0.8%
Dia. on % (80.0%) : 5.274µm % on Dia. (0.100µm) : 0.0%
Dia. on % (70.0%) : 4.108µm % on Dia. (1.000µm) : 36.8%




Figure 9

1% Compound B and 0.25% Tween 80

Condition
T%(He-Ne): 88.0%
(LAMP): 88.8%
Dist. Form: Std
R.R. Index: 1.20-0.101
Sampling time: 15
Agitation : 2
Cloutln : 2
U.sonlo : ON(30)
Format
Dist. base : Volume
Scaling : Auto
Axis : LogX - Linear
Data
Median : 2.872µm
BP. Area: 47473cm²/cm²
S.D. : 2.575µm
Mode : 4.172µm
Mean : 3.215µm
C.V. : 80.08%
Span : (D 10.0-D 90.0) / D50 = 2.385
Dia. on % (90.0%) : 8.832µm
% on Dia. (0.400µm) : 7.3%
Dia. on % (80.0%) : 2.872µm
% on Dia. (0.300µm) : 2.8%
Dia. on % (65.0%) : 8.244µm
% on Dia. (0.200µm) : 0.4%
Dia. on % (50.0%) : 5.280µm
% on Dia. (0.100µm) : 0.0%
Dia. on % (30.0%) : 4.208µm
% on Dia. (1.000µm) : 24.8%




Figure 10


2% Compound B and 2% tyloxapol



Figure 11

2% Compound B and 1% PEG-5000 Phospholipid

Condition
T% (He-Ne): 88.1%
(LAMP): 88.3%
Dist. Form: Std.
R.R. Index: 1.20-0.101 { Sampling time: 15 }
Agitation : 2 Circulin : 2 U.sonic : ON(30)
Format
Dist. base : Volume Scaling : Auto Axis : LogX - LinearY
Data
Median : 0.188µm SP. Area: 321049cm²/cm² S.D. : 0.040µm
Mode : 0.185µm Mean : 0.194µm
C.V. : 20.42%
Span : (D 10.0-D 90.0) / D50 = 0.468
Dia. on % (90.0%) : 0.241µm % on Dia. (0.400µm) : 98.7%
Dia. on % (80.0%) : 0.188µm % on Dia. (0.300µm) : 98.0%
Dia. on % (70.0%) : 0.260µm % on Dia. (0.200µm) : 84.7%
Dia. on % (60.0%) : 0.218µm % on Dia. (0.100µm) : 0.0%
Dia. on % (50.0%) : 0.206µm % on Dia. (1.000µm) : 100.0%



BEST AVAILABLE COPY